ViGenCell Inc.
KOSDAQ-listed biotech venture developing cell therapies including ViTier for lymphoma and ViMedier for graft-versus-host disease.
As of 2026-10-10, ViGenCell Inc. has 5 Korean MFDS device approvals, 11 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2013 and listed on KOSDAQ in 2021, ViGenCell is a biotech venture specializing in immune cell therapies. Its pipeline includes ViTier (VT-EBV-N) for lymphoma, EiNK (VC-302, VC-420) for glioblastoma and hepatocellular carcinoma, and ViMedier (VM-GD) for graft-versus-host disease. VT-EBV-N has completed Phase 2 trials and is preparing for conditional approval, while VC-302, VC-420, and VM-GD remain preclinical, with VM-GD having standardized and patented an improved culture method; as of fiscal year 2023 (11th term), other merchandise accounted for 258 (92.7% of revenue), with no product revenue yet from cell therapies.
Regulatory approvals
data.go.kr1 Orphan Drug designations · 2019 / 5 Korean MFDS device approvals · 2023–2024
- OrphanVT-EBV-N2019-10-04Orphan Drug designation · in development20190147316
- MFDSIVD reagents for histocompatibility antigen, antibody not for transfusion or transplantation but for specific disease diagnosis, molecular diagnosticsRevoked2024-10-08Product approval · Class 2체외 제인 24-915 호
- MFDSIVD reagents for pharmacogeneticsRevoked2024-09-30Product approval · Class 3체외 제허 24-661 호
- MFDSIVD reagents for histocompatibility antigen, antibody not for transfusion or transplantation but for specific disease diagnosis, molecular diagnosticsRevoked2024-08-16Product approval · Class 2체외 제인 24-784 호
- MFDSIVD reagents for histocompatibility antigen, antibody not for transfusion or transplantation but for specific disease diagnosis, molecular diagnosticsRevoked2023-02-13Product approval · Class 2체외 제인 23-4153 호
- MFDSIVD reagents for histocompatibility antigen, antibody not for transfusion or transplantation but for specific disease diagnosis, molecular diagnosticsRevoked2023-01-25Product approval · Class 2체외 제인 23-4087 호
Clinical trials
data.go.kr3 MFDS clinical trial authorisations · 2017–2020 (Phase 1/2a 1 · Phase 1 1 · Phase 2 1)
- Phase 1/2aVM-0012020-11-23
1 trial site
- Phase 1VT-Tri2020-09-21
7 trial sites
- Phase 2VT-EBV-N2017-12-26
12 trial sites
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1/2 · Unknown · 2022-11 · NCT05276076
Phase 2 · Unknown · 2019-04 · NCT03671850
R&D and key agreements
Source: DART corporate disclosureViTier (VT-EBV-N) · NK/T세포 림프종 · 임상 2상 완료, 조건부 품목허가 준비 · Cell type: CTL (cytotoxic T lymphocyte), autologous
EiNK (VC-302) · 교모세포종 · 전임상 진행중 · Cell type: iPSC-derived NK cell, allogeneic/off-the-shelf
EiNK (VC-420) · 간세포암 · 전임상 진행중 · Cell type: iPSC-derived NK cell, allogeneic/off-the-shelf
ViMedier (VM-GD) · 이식편대숙주질환(GVHD) · 전임상 진행중 · Cell type: MDSC, allogeneic; improved culture method standardized and patented; preparing manufacturing site change to new in-house facility
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- A walk through the development of human leukocyte antigen typing: from serologic techniques to next-generation sequencing.
Clinical transplantation and research · 2024-12 · Choi H, Choi EJ, Kim HJ 외 5
- Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion.
NPJ precision oncology · 2024-05 · Lee SH, Kim K, Lee E 외 25
- Local Myeloid-Derived Suppressor Cells Impair Progression of Experimental Autoimmune Uveitis by Alleviating Oxidative Stress and Inflammation.
Investigative ophthalmology & visual science · 2023-10 · Lee JY, Kim S, Sohn HJ 외 3
- Skin repair and immunoregulatory effects of myeloid suppressor cells from human cord blood in atopic dermatitis.
Frontiers in immunology · 2023-01 · Kim CH, Hong SM, Kim S 외 5
- Local and Systemic Injections of Human Cord Blood Myeloid-Derived Suppressor Cells to Prevent Graft Rejection in Corneal Transplantation.
Biomedicines · 2022-12 · Lee JY, Sohn HJ, Kim CH 외 2
- Efficient Anti-Tumor Immunotherapy Using Tumor Epitope-Coated Biodegradable Nanoparticles Combined With Polyinosinic-Polycytidylic Acid and an Anti-PD1 Monoclonal Antibody.
Immune network · 2022-10 · Kim SH, Park JH, Lee SJ 외 8
- γδ T cells cultured with artificial antigen-presenting cells and IL-2 show long-term proliferation and enhanced effector functions compared with γδ T cells cultured with only IL-2 after stimulation with zoledronic acid.
Cytotherapy · 2021-10 · Choi H, Lee Y, Hur G 외 6
- An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia.
British journal of cancer · 2020-09 · Shin AR, Lee SE, Choi H 외 3
- T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity.
Cancer research and treatment · 2020-07 · Lee SE, Shin AR, Sohn HJ 외 2
- Comprehensive Analysis of CD4+ T Cell Responses to CMV pp65 Antigen Restricted by Single HLA-DR, -DQ, and -DP Allotype Within an Individual.
Frontiers in immunology · 2020-01 · Hyun YS, Jo HA, Lee YH 외 5
Show 1 more publications
Patents
KIPRIS · applicant-matchedPCT · Published · 2025-08 · Application PCT/KR2025/012653
Published · 2024-08 · Application 1020240112896
Published · 2023-03 · Application 1020230041676
CN · Published · 2023-03 · Application 202380022590.5
US · Published · 2023-03 · Application 18834896
PCT · Published · 2023-03 · Application PCT/KR2023/004241
PCT · Published · 2022-02 · Application PCT/KR2022/001747
Rejected · 2021-06 · Application 1020210076613
US · Published · 2021-06 · Application 18569023
PCT · Published · 2021-06 · Application PCT/KR2021/007420
Show 3 more patents
Rejected · 2021-02 · Application 1020210016857
Registered · 2011-04 · Application 1020110037522
Registered · 2010-12 · Application 1020100127882
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIOAI-SearchBot25
- GoogleGoogleOther2
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for ViGenCell Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.
KOSDAQ-listed molecular genetic diagnostics company providing NGS-based non-invasive prenatal testing (NIPT) under the MomGuard brand.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
Supplies synthetic genes (GenOligo) and DNA sequencing analysis services for biotech research.
Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition